PDS Biotechnology Corporation
General ticker "PDSB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $51.0M (TTM average)
PDS Biotechnology Corporation follows the US Stock Market performance with the rate: 15.6%.
Estimated limits based on current volatility of 3.1%: low 0.70$, high 0.74$
Factors to consider:
- Total employees count: 21 (-12.5%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Significant losses, Clinical trial failure, Regulatory and compliance, Capital raising
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.54$, 2.15$]
- 2026-12-31 to 2027-12-31 estimated range: [0.71$, 2.52$]
Financial Metrics affecting the PDSB estimates:
- Positive: with PPE of -1.1 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: 19.19 < Shareholder equity ratio, % of 30.34 <= 42.57
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Positive: Inventory ratio change, % of 0 <= 0
Short-term PDSB quotes
Long-term PDSB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $43.05MM | $36.32MM | $31.54MM |
| Operating Income | $-43.05MM | $-36.32MM | $-31.54MM |
| Non-Operating Income | $-1.30MM | $-2.16MM | $-4.12MM |
| Interest Expense | $5.51MM | $4.67MM | $5.34MM |
| R&D Expense | $27.76MM | $22.57MM | $19.03MM |
| Income(Loss) | $-44.35MM | $-38.48MM | $-35.67MM |
| Taxes | $-1.41MM | $-0.87MM | $-1.17MM |
| Net Income(Loss)* | $-42.94MM | $-37.61MM | $34,426.51MM |
| Stockholders Equity | $26.13MM | $19.00MM | $9.25MM |
| Assets | $59.39MM | $45.36MM | $30.49MM |
| Operating Cash Flow | $-33.64MM | $-35.03MM | $-27.75MM |
| Capital expenditure | $0.00MM | $0.03MM | $0.00MM |
| Investing Cash Flow | $0.00MM | $-0.03MM | $0.00MM |
| Financing Cash Flow | $16.38MM | $20.19MM | $12.77MM |
| Earnings Per Share** | $-1.39 | $-1.03 | $742.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.